WO1997004756A3 - Methacrylate backbone surfactants in nanoparticulate formulations - Google Patents

Methacrylate backbone surfactants in nanoparticulate formulations Download PDF

Info

Publication number
WO1997004756A3
WO1997004756A3 PCT/US1996/011777 US9611777W WO9704756A3 WO 1997004756 A3 WO1997004756 A3 WO 1997004756A3 US 9611777 W US9611777 W US 9611777W WO 9704756 A3 WO9704756 A3 WO 9704756A3
Authority
WO
WIPO (PCT)
Prior art keywords
surfactants
nanoparticulate formulations
methacrylate backbone
methacrylate
drug substance
Prior art date
Application number
PCT/US1996/011777
Other languages
French (fr)
Other versions
WO1997004756A2 (en
Inventor
Sui-Ming Wong
Original Assignee
Nanosystems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanosystems Llc filed Critical Nanosystems Llc
Priority to AU65464/96A priority Critical patent/AU6546496A/en
Publication of WO1997004756A2 publication Critical patent/WO1997004756A2/en
Publication of WO1997004756A3 publication Critical patent/WO1997004756A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476—Particles, beads, capsules, spheres
    • A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/049—Surface-modified nanoparticles, e.g. immune-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

Nanoparticles having an effective average particle size diameter of less than 100 nm comprising a crystalline organic drug substance and a copolymer of methoxypolyethyleneglycol-methacrylate-methoxymethacrylate adsorbed on the surface of the crystalline organic drug substance.
PCT/US1996/011777 1995-07-26 1996-07-16 Methacrylate backbone surfactants in nanoparticulate formulations WO1997004756A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU65464/96A AU6546496A (en) 1995-07-26 1996-07-16 Methacrylate backbone surfactants in nanoparticulate formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US198595P 1995-07-26 1995-07-26
US60/001,985 1995-07-26
USNOTFURNISHED 2005-06-27

Publications (2)

Publication Number Publication Date
WO1997004756A2 WO1997004756A2 (en) 1997-02-13
WO1997004756A3 true WO1997004756A3 (en) 1997-03-27

Family

ID=21698707

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/011777 WO1997004756A2 (en) 1995-07-26 1996-07-16 Methacrylate backbone surfactants in nanoparticulate formulations

Country Status (2)

Country Link
AU (1) AU6546496A (en)
WO (1) WO1997004756A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19911041A1 (en) * 1999-03-12 2000-09-14 Henkel Kgaa Flexible and absorbent carriers for treating the skin equipped with nanoparticle dispersions
US6878693B2 (en) 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
CA2461890C (en) * 2001-09-28 2010-12-14 Solubest Ltd. Water soluble nanoparticles of hydrophilic and hydrophobic active materials
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7226968B2 (en) * 2003-05-20 2007-06-05 Arch Uk Biocides Limited Composition and use
US7217759B2 (en) * 2003-05-20 2007-05-15 Arch Uk Biocides Limited Composition and use
AU2004275594A1 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles inclusion complexes
US7846412B2 (en) * 2003-12-22 2010-12-07 Emory University Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof
GB0516549D0 (en) 2005-08-12 2005-09-21 Sulaiman Brian Milling system
BRPI0622191B8 (en) * 2006-12-07 2021-06-22 Toyo Boseki use of a methacrylate copolymer in the manufacture of an antithrombogenic medical device, and use of a methacrylate copolymer as an antithrombogenic material for surface treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078994A (en) * 1990-04-12 1992-01-07 Eastman Kodak Company Microgel drug delivery system
EP0577215A1 (en) * 1992-07-01 1994-01-05 NanoSystems L.L.C. Surface modified anticancer nanoparticles
EP0601619A2 (en) * 1992-12-04 1994-06-15 NanoSystems L.L.C. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078994A (en) * 1990-04-12 1992-01-07 Eastman Kodak Company Microgel drug delivery system
EP0577215A1 (en) * 1992-07-01 1994-01-05 NanoSystems L.L.C. Surface modified anticancer nanoparticles
EP0601619A2 (en) * 1992-12-04 1994-06-15 NanoSystems L.L.C. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization

Also Published As

Publication number Publication date
AU6546496A (en) 1997-02-26
WO1997004756A2 (en) 1997-02-13

Similar Documents

Publication Publication Date Title
CA2340221A1 (en) Injectable formulations of nanoparticulate naproxen
CA2118517A1 (en) Surface modified nsaid nanoparticles
WO2002062881A3 (en) Foam including surface-modified nanoparticles
CA2202732A1 (en) Filled and polymerizable dental material
WO2004019999A3 (en) Agent delivery particle
USD412270S (en) Article lifter
CA2098242A1 (en) Surface modified anticancer nanoparticles
WO1997004756A3 (en) Methacrylate backbone surfactants in nanoparticulate formulations
CA2424082A1 (en) Surface modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media
NZ332299A (en) Oral sustained release containing a hydrophilic and hydrophobic layer especially for medicaments containing nifedipine
CA2409292A1 (en) Tablets and methods for modified release of hydrophilic and other active agents
DE69627835D1 (en) SOLID PHARMACEUTICAL COMPOSITION OF NANOPARTICLES
HU9200226D0 (en) Active agent particles with modified cover
EP2092936A3 (en) Tamper-resistant oral opioid agonist formulations
EP1249047A4 (en) Electrodes including particles of specific sizes
EP2360298A3 (en) Method for depositing a semiconductor nanowire
AU4900996A (en) Compositions comprising nanoparticles of nsaid
EP1806600A3 (en) Anti-reflection film and display device using the same
AU3495595A (en) Nanoscale particles, and uses for same
EP0863544A3 (en) Substrate for use in wafer attracting apparatus and manufacturing method thereof
AU9746598A (en) Amphiphilic particles or molecules with predominantly hydrophilic and predominantly hydrophobic domains distributed anisotropically on their surface
AU2002213854A1 (en) Surface active random radical (co)polymer and dispersion method for using the same
EP1210942A3 (en) Microparticles
AU6016999A (en) Nanometer sized particles containing a reactive monolayer adsorbed thereon and methods of making the same
CA2290973A1 (en) Encapsulated solution dosage forms of sertraline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA